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AbstrAct
Introduction Sepsis is associated with a dysregulated host 
response to infection and impaired endogenous corticosteroid 
metabolism. As such, therapeutic use of exogenous 
corticosteroids is a promising adjunctive intervention. Despite 
a large number of trials examining this research question, 
uncertainty persists regarding the effect of corticosteroids on 
survival in sepsis. Several large randomised controlled trials 
have been published recently prompting a re-evaluation of 
the available literature.
Methods and analysis A rigorous and reproducible search 
and screening process from a Cochrane review on the same 
topic was comprehensive to October 2014. We will search 
MEDLINE, EMBASE, LILACS, the Cochrane trial registry and  
clinicaltrials. gov for eligible randomised controlled trials 
investigating the use of corticosteroids in patients with sepsis 
from September 2014. Outcomes have been chosen by a 
semi-independent guideline panel, created in the context 
of a parallel BMJ Rapid Recommendation on the topic. This 
panel includes clinicians, content experts, methodologists 
and patient representatives, who will help identify patient-
important outcomes that are critical for deciding whether 
to use or not use corticosteroids in sepsis. Two reviewers 
will independently screen and identify eligible studies; a 
third reviewer will resolve any disagreements. We will use 
RevMan to pool effect estimates from included studies for 
each outcome using a random-effect model. We will present 
the results as relative risk with 95% CI for dichotomous 
outcomes and as mean difference or standardised mean 
difference for continuous outcomes with 95% CI. We will 
assess the certainty of evidence at the outcome level using 
the Grading of Recommendations, Assessment, Development 
and Evaluation approach. We will conduct a priori subgroup 
analyses, which have been chosen by the parallel BMJ Rapid 
Recommendation panel.
Ethics and dissemination The aim of this systematic review 
is to summarise the updated evidence on the efficacy and 
safety of corticosteroids in patients with sepsis.
Trial registration number CRD42017058537.
Background
description of the condition
Sepsis is defined as a life-threatening organ 
dysfunction caused by a dysregulated host 
response to infection.1 The primary immune 
mechanisms include hyperstimulation of the 
inflammatory cascade and upregulation of 
related cytokines (including tumour necrosis 
factor-α, interleukin (IL)-1, IL-6). Haemody-
namic instability secondary to vasodilation and 
dysregulation of coagulation and fibrinolysis 
are key contributors to tissue hypoperfusion 
and organ injury.2 Septic shock is defined 
by the need for vasopressors to maintain a 
mean arterial pressure over ≥65 mm Hg and 
a serum lactate >2 mmol/L in the absence of 
hypovolaemia.
The incidence of sepsis varies from 900 000 
to 3 million cases in the USA per year 
depending on the epidemiological method-
ology employed.3 4 In-hospital mortality of 
sepsis ranges from 14.7% to 30% in children 
and adults.3 5 Although hospital mortality 
rates from sepsis may have declined over the 
last 20 years, the incidence of sepsis seems to 
be increasing.6
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Protocol
Strengths and limitations of this study
 ► Systematic and comprehensive search.
 ► Multidisciplinary team including oversight 
and input from semi-independent BMJ 
Rapid  Recommendation panel which includes 
patient and carer representatives.
 ► The results of this review will directly inform BMJ 
Rapid  Recommendation clinical practice guideline 
recommendation.
 ► Application of Grading of Recommendations, 
Assessment, Development and Evaluation 
methodology to assess certainty in summarised 
estimates of effect.
 ► Anticipated clinical heterogeneity in individual study 
populations and intervention (including dosing, 
timing and formulation of corticosteroids).
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description of intervention
The sympathetic nervous system is activated by external 
stressors, such as sepsis, leading to the release of endog-
enous catecholamines and cortisol from the adrenal 
glands. Cortisol is the major endogenous glucocorticoid 
in the body and downregulates production of inflamma-
tory cytokines through inhibition of nuclear factor-κB.7 
Cortisol also has other physiological effects in the body 
including increasing glucose levels (through enhanced 
hepatic gluconeogenesis and decreased peripheral 
glucose uptake) and increasing blood pressure (via 
increasing sensitivity to catecholamines).
Corticosteroids are synthetic cortisol compounds, which 
exert similar effects to their endogenous counterparts. In 
addition to glucocorticoid activity, many synthetic corti-
costeroids also have mineralocorticoid components that 
serve as substrate precursors for catecholamine synthesis.8 
Some of the corticosteroids that have been investigated in 
the setting of sepsis include hydrocortisone,9–16 methyl-
prednisolone17–20 and prednisone.21 22 Dosing regimens 
vary considerably with some studies giving large doses 
over 2–3 days and then stopping and others giving lower 
doses over 1–2 weeks with a gradual taper.
How the intervention might work
Cortisol deficiency in sepsis is likely multifactorial, usually 
reversible and results in an inadequate amount of cortisol 
at the tissue level.23 Likewise, tissue resistance to cortico-
steroids is multifactorial and may involve alteration in the 
number or function of glucocorticoid receptors, cortisol 
metabolism or access to tissues. The result of removing this 
‘check’ on the host immune response is unregulated acti-
vation of the inflammatory cascade leading to end-organ 
dysfunction. Also, the relative deficiency of mineralocor-
ticoids may further contribute to systemic hypoperfusion, 
a subsequent decrease in oxygenated blood delivery to 
the periphery and further end-organ damage.
Exogenous supplementation with agents that have both 
glucocorticoid and mineralocorticoid activity is therefore 
a promising therapeutic option in patients with sepsis.
Why it is important to do this review
Despite strong physiological rationale for administra-
tion of corticosteroids in sepsis, uncertainty regarding 
the overall clinical effectiveness and the challenge of 
identifying patients who may benefit from their use has 
ultimately led to a high degree of practice variation.24 25 
In the 55 years since the first randomised controlled trial 
(RCT) of corticosteroids in sepsis, their utility remains 
debated in the management of critically ill patients. The 
most recent systematic review suggested that steroids may 
reduce mortality in sepsis, although conclusions were 
based on low certainty in the evidence and were limited 
by imprecision, inconsistency and the potential for publi-
cation bias.26 Results from this review suggested that 
patients with septic shock and those treated with a low 
dose and long course of corticosteroids had the highest 
likelihood of benefit.
Since the most recently published review, an addi-
tional large RCT was published27 and another is planned 
for publication shortly.28 Our updated systematic review 
and meta-analysis will include these two new trials, and 
any others identified in the updated search, in order to 
improve precision of the pooled point estimates of the 
treatment effect of corticosteroids in patients with sepsis. 
The new trials will provide data for at least 1600 additional 
patients from what we expect are trials at low risk of bias. 
This will substantially improve the power to detect clini-
cally important effects; the previous review included 4200 
patients from trials with various degrees of credibility.
This systematic review is part of the BMJ Rapid Recom-
mendation project, a collaborative effort from the MAGIC 
research and innovation programme (www. magicproject. 
org) and The BMJ.29 The aim of the project is to respond to 
new potentially practice-changing evidence and provide 
a trustworthy practice guideline in a timely manner. 
The anticipated publication of the APROCCHSS trial,30 
a multicentre trial that randomised 1241 patients with 
septic shock to receive hydrocortisone and fludrocorti-
sone or placebo, is the trigger for this updated review. 
This systematic review will inform a parallel clinical prac-
tice guideline which will be published in a multilayered 
electronic format on The BMJ and MAGICapp.
objectives
We plan to conduct a systematic review and meta-analysis 
of all published RCTs that have investigated the use of 
corticosteroids in critically ill patients with sepsis.
MeTHods
studies
We plan to include all RCTs reporting the use of cortico-
steroids in critically ill patients with sepsis. We will exclude 
case reports, case series and observational studies. We 
will not impose any methodological quality or language 
restrictions to the studies included and will appraise their 
risk of bias (see corresponding section below).
Participants
The population of interest includes all adult and chil-
dren (excluding premature infants due to higher rates of 
adrenal insufficiency in this population31) who were diag-
nosed with sepsis, severe sepsis or septic shock according 
to appropriate criteria.1 32 33 We will include data from 
trials enrolling patients with acute respiratory distress 
syndrome if patients with sepsis are reported separately.
Interventions and comparators
The intervention of interest is the administration of 
systemic corticosteroids, including but not limited to 
cortisone, hydrocortisone, methylprednisolone, beta-
methasone, fludrocortisone and dexamethasone. We will 
only include RCTs with a placebo or no corticosteroid 
comparator group.
For the purposes of this review, high-dose cortico-
steroids will be considered any dose >400 mg/day of 
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hydrocortisone or equivalent. Similarly, long duration 
of corticosteroid treatment will be considered ≥3 days. 
These operational definitions are rationalised based on 
a change in philosophy regarding the role of cortico-
steroids in sepsis that occurred in the late 1990s. Older 
studies administered very-high-dose and short duration 
corticosteroids attempting to maximise their anti-inflam-
matory effect, whereas newer studies used lower-dose 
and longer duration corticosteroids with the intent of 
compensating for a dysfunctional hypothalamic-pituitary 
axis response to stress.
outcome measures
Patient-important outcomes have been chosen by a 
semi-independent parallel BMJ Rapid Recommendation 
guideline panel and include the outcomes that are critical 
for choosing whether to use corticosteroids in sepsis.34
The outcomes are
 ► short-term mortality;
 ► 90-day mortality;
 ► 28-day, 30-day, hospital, intensive care unit (ICU) 
mortality (whichever is available);
 ► long-term mortality (closest to 1 year);
 ► number of participants with shock reversal at day 7 
(stable haemodynamic status over 24 hours after 
withdrawal of vasopressors);
 ► organ dysfunction at day 7 (using total SOFA score);
 ► ICU length of stay;
 ► hospital length of stay;
 ► adverse events associated with corticosteroids 
including ICU-acquired neuromuscular weakness, 
gastrointestinal bleeding, neuropsychiatric effects, 
hypernatremia, superinfection, vascular events 
(stroke, myocardial infarction) and clinically 
significant hyperglycaemia;
 ► quality of life (using validated indices such as SF-36) 
at 1 year.
search methods for identification of studies
A search and screening process from a Cochrane review 
on the same topic was credible and comprehensive to 
October 2014.35 Using the same search strategy, we will 
search MEDLINE, EMBASE, LILACS and the Cochrane 
trial registry for RCTs investigating the use of cortico-
steroids in patients with sepsis from a database entry 
date of September 2014. We will not use any language 
restrictions. See online supplementary appendix 1 for 
MEDLINE search strategy. Keyword search terms include 
corticosteroids, sepsis and septic shock.
searching other resources
We will search the references of review articles and 
systematic reviews on the same topic for eligible articles. 
In addition, we will search for unpublished or ongoing 
trials on the WHO international clinical trials registry, 
current controlled trials metaregister of controlled trials 
and  clinicaltrials. gov database. Two reviewers will search 
conference proceedings from the Society of Critical Care 
Medicine, American Thoracic Society and the European 
Society of Intensive Care Medicine (2014 and onwards).
data collection and analysis
On implementation of our search strategy, reviewers 
working in pairs will independently screen all cita-
tions and references using specific eligibility criteria. If 
disagreements between the two primary reviewers cannot 
be resolved by discussion and consensus, a third reviewer 
will make the final determination of trial eligibility. We 
will attempt to contact study authors to obtain missing 
information necessary to judge trial eligibility.
data extraction and management
Data extraction will be done independently and in dupli-
cate using predesigned data abstraction forms. Abstracted 
data will include study title, first author, relevant demo-
graphic data, details of the intervention and control, 
primary and secondary outcome data, and information 
on methodological quality for each study. A third reviewer 
will resolve inconsistent data extraction between the two 
reviewers. We will perform data collection on studies 
included in the previous review35 only for outcomes or 
subgroups that were not previously reported.
assessment of risk of bias in included studies
Two reviewers will independently assess the risk of bias 
for each included study using the modified version of 
the Cochrane Collaboration tool.36 Risk of bias assess-
ment will be performed for individual studies separately 
for each outcome. A third reviewer will resolve disagree-
ments.
The included RCTs will be assessed for sequence 
generation, allocation sequence concealment, blinding, 
selective outcome reporting and missing participant data. 
Sequence generation will be considered adequate if the 
study explicitly described an appropriate randomisation 
procedure to generate an unpredictable sequence of 
allocation, including computerised randomisation, use 
of random number tables and coin-tossing. Conceal-
ment of allocation will be considered adequate if specific 
methods to protect allocation were documented and 
implemented. Performance bias will be considered low if 
a study reported participant, caregiver and/or researcher 
blinding. Blinding of outcome assessment will be consid-
ered adequate if outcome assessors and adjudicators were 
blinded. Within-study selective reporting of outcomes will 
be examined by reviewing the a priori study protocol, if 
available. If the study protocol is not available, we will 
compare the outcomes listed in the methods section with 
the reported outcomes in the results section.
A description for each domain assessed will be included 
along with comments if necessary and a final judgement 
for each outcome within each study and categorised as 
(1) low risk of bias, where bias is not present or, if present, 
unlikely to affect outcomes; (2) probably low risk of bias; 
(3) probably high risk of bias; or (4) high risk of bias, 
where outcomes are likely to be significantly affected 
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by bias. We will consider the highest risk of bias for any 
criteria as the overall risk of bias for the study.
Measures of treatment effect
We will use RevMan V.5.3 software to conduct meta-anal-
yses. We will use the method of DerSimonian and Laird 
for random-effects model to pool effect sizes for each 
outcome. Study weights will be generated using the 
inverse variance method. We will present the results as 
relative risk with 95% CI for dichotomous outcomes 
and as mean difference (MD) or standardised MD for 
continuous outcomes with 95% CI. We plan to perform 
random-effect analysis for all outcomes of interest.
We will use the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach 
to quantify the absolute magnitude of effect. We will 
use representative and trustworthy observational studies 
to measure baseline risk and apply the relative effect 
measured from the meta-analysis to obtain absolute 
differences (risk difference or MD) with a 95% CI. The 
risk difference with 95% CI will be derived from pooled 
risk ratios and its 95% CI using assumed control risk for 
each outcome.37
dealing with missing data
Where possible, if missing data are encountered we will 
attempt to contact the individual study authors for addi-
tional information. If this is not possible, we will analyse 
the available data and report on the potential impact of 
missing data on the results in the discussion section. We 
will perform a complete case analysis as the primary anal-
ysis for all outcomes and perform sensitivity analyses with 
increasingly extreme assumptions for missing participant 
data.38
assessment of reporting biases
We will look for potential publication bias using a funnel 
plot if >10 trials are included. For continuous outcomes, 
the Egger test39 will be used to detect funnel plot asym-
metry. For dichotomous outcomes, the arcsine test will be 
used. All analyses will be performed using RevMan or R.
subgroup analysis and investigation of heterogeneity
We will assess for heterogeneity between studies using the 
χ2 test for homogeneity, where p<0.10 indicates substan-
tial heterogeneity, and the I² statistic, in addition to visual 
inspection of the forest plots for magnitude of differ-
ences. If subgroup effects are credible, we will present 
the outcomes separately for each subgroup.40 If serious 
heterogeneity remains, we will rate down our certainty in 
the effect estimate.41
We will conduct a priori subgroup analyses, which were 
chosen by the parallel BMJ Rapid Recommendation panel 
(hypothesised direction of effect in parentheses):
 ► risk of bias (corticosteroids more effective in trials 
with high risk of bias);
 ► treatment dose (corticosteroids more effective in trials 
with lower doses);
 ► treatment duration (corticosteroids more effective in 
trials with longer duration);
 ► treatment molecule (corticosteroids more effective 
in trials with drugs having more mineralocorticoid 
activity);
 ► sepsis population subtype (sepsis, septic shock, 
pneumosepsis) (corticosteroids most effective in 
patients with pneumonia and those with septic shock, 
and least effective in patients with non-pneumonia 
sepsis without shock);
 ► age of patients (corticosteroids more effective in 
studies enrolling children (<18 years) than adults);
 ► presence of critical illness-related corticosteroid 
insufficiency (CIRCI) (corticosteroids more effective 
in trials identifying and enrolling patients with 
CIRCI).
For subgroup analyses, we will perform meta-regression if 
a sufficient number of studies are found (generally >10). 
If not, we will use the χ2 test for each subgroup hypoth-
esis, and then meta-regression if more than one is found 
to be statistically significant (using a p value threshold 
of <0.10).
sensitivity analysis
Sensitivity analysis will be performed excluding studies 
only reported as abstracts.
assessing the certainty of evidence
The GRADE approach will be used to assess the certainty 
of evidence for each outcome.42 The GRADE system clas-
sifies the certainty of the aggregate body of evidence as 
high, moderate, low or very low. The evidence will be eval-
uated using the following criteria: (1) study design and 
rigour of its execution (ie, individual study risk of bias), 
(2) the extent to which the evidence could be applied to 
patients of interest (ie, directness), (3) the consistency of 
results, (4) the analysis of the results (ie, precision) and 
(5) whether there is a likelihood of publication bias.
For each outcome, a final overall certainty of evidence 
will be summarised for the intervention taking into 
consideration both desirable and undesirable outcomes. 
An evidence profile will be included in the results showing 
the GRADE assessments and pooled analysis per outcome.
guIdelIne Panel and PaTIenT InvolveMenT
According to the BMJ Rapid Recommendations 
process,34 the guideline panel has already provided crit-
ical oversight and identified populations, subgroups and 
outcomes of interest for this review. The panel includes 
content experts, methodologists and patients or carers 
with personal experience with sepsis. The panel is consid-
ered semi-independent of the systematic review team as 
four individuals are members of both. All patients receive 
personal training and support to optimise contributions 
throughout the guideline development process. The 
patient panel members will be invited to lead the inter-
pretation of the results based on what they expect the 
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typical patient values and preferences to be, as well as the 
variation between patients.
dIscussIon
Despite a large body of evidence, the role of corticosteroids 
in sepsis remains controversial. Given the forthcoming 
availability of new data addressing this research question, 
an updated systematic review and meta-analysis is needed 
to generate the best summary of evidence in order to 
help guideline developers and to assist bedside clinicians. 
This systematic review will summarise the RCT data on 
the efficacy and safety of corticosteroid use in critically 
ill patients with sepsis. Also, as future trial results become 
available (eg, NCT01448109) we will be able to rapidly 
incorporate the results into this evidence summary.
Strengths of this protocol include a comprehensive 
search strategy of published and unpublished literature, 
a priori subgroup analysis plan and inclusion of GRADE 
methodology to characterise the certainty in evidence 
and confidence in the estimates of effect. Results of this 
review will be accompanied by a BMJ Rapid Recommen-
dation34 43–45 for front-line clinicians. Limitations relate 
to the anticipated clinical heterogeneity of patients, 
corticosteroid regimens and outcome assessments from 
included studies.
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